Incyte Backs AI Screening and Caregiver Research for GVHD

WILMINGTON, DE — Incyte is supporting two research initiatives aimed at improving early detection of graft-versus-host disease complications and addressing caregiver needs, selecting the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute for its 2026 Ingenuity Awards in GVHD.

The projects target separate challenges associated with graft-versus-host disease, or GVHD, a complication that can occur following stem cell transplantation. One will develop an artificial intelligence-based screening system for eye complications, while the other will examine the demands placed on caregivers of patients with chronic GVHD.

The University of Maryland project, called Ocular Surface Imaging Guidance and Health Triage, or OSIGHT, will develop and evaluate an AI-enabled screening platform for use in transplant clinics.

READ:  Phreesia Sets Dec. 2 Release for Quarterly Earnings

The system is designed to combine ocular imaging, clinical measurements and patient-reported symptoms to identify patients at risk of ocular GVHD and facilitate referrals to ophthalmology specialists.

Earlier identification could help clinicians intervene before complications cause further vision impairment, while improving coordination between transplant teams and eye specialists.

Moffitt Cancer Center’s project will focus on caregivers supporting people with chronic GVHD, examining the psychological, practical and other challenges associated with managing the condition.

Researchers plan to conduct in-depth interviews to identify caregiver stressors, unmet needs and gaps in available support resources.

The findings are intended to inform future caregiver assistance programs and will be disseminated to organizations and professionals involved in GVHD care.

READ:  Visiting Angels Warns Seniors of Rising Holiday Cyber Scams

“GVHD can profoundly impact both patients and those who care for them,” said Mohamed Issa, Incyte’s executive vice president and head of U.S. commercial.

Issa said the selected projects address needs ranging from earlier identification of ocular complications to a better understanding of caregiver challenges.

The awards are part of Incyte’s annual program supporting projects intended to improve care and resources for people affected by GVHD, including patients, caregivers and healthcare professionals.

Applications were reviewed by an independent panel of clinicians, researchers and patient advocates.

The panel included Hugo Fernandez, a hematology and cellular therapy specialist affiliated with Memorial Healthcare System and the University of South Florida; Christina Ferraro of Cleveland Clinic Cancer Institute; Kathleen D. Lyons, a cancer rehabilitation researcher at Mass General Brigham University of Health Professions; and Lynne Spina, director of development and marketing at BMT InfoNet.

READ:  Incyte Advances Blood Cancer Drugs Ahead of December Data Release

Judges affiliated with an applicant organization were excluded from evaluating that organization’s submission.

The two selected initiatives address different stages of GVHD management: identifying potentially serious complications earlier in clinical care and developing evidence to guide support for caregivers managing the disease’s longer-term effects.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.